外部对照在杜氏肌营养不良药物评价中的适用性
本研究评估真实世界数据(RWD)和自然史数据(NHD)作为外部对照用于门诊杜氏肌营养不良(DMD)药物评价的适用性。通过文献回顾确定6个安慰剂组(n=383),并纳入5个RWD/NHD来源(n=430),比较48周6分钟步行距离变化(Δ6MWD)。结果显示,在应用相同入排标准后,安慰剂组与RWD/NHD的Δ6MWD差异无统计学意义,未检测到系统性偏倚。
要点
- 应用相同入排标准后,安慰剂组与RWD/NHD的Δ6MWD差异无统计学意义。
- 未检测到RWD/NHD作为外部对照的系统性偏倚。
- RWD/NHD有望补充或替代DMD试验中的安慰剂对照。
核心结论
- 在应用相同入排标准后,安慰剂组与RWD/NHD的Δ6MWD一致,未发现系统性偏倚。
研究设计与样本
- 通过文献回顾确定6个安慰剂组(n=383),代表4套入排标准。
- 纳入5个RWD/NHD来源(n=430),分析约1200患者年随访数据。
主要发现
- 安慰剂组与RWD/NHD队列的Δ6MWD均值差异范围为-19.4米至19.5米,均无统计学意义。
- 协变量调整前后差异均无统计学意义。
关键数值与推荐
- 6个安慰剂组报告48周Δ6MWD,总样本量383例。
- RWD/NHD来源总样本量430例。
临床怎么用
- RWD/NHD可用于补充或可能替代DMD试验中的安慰剂对照。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the suitability of real-world data (RWD) and natural history data (NHD) for use as external controls in drug evaluations for ambulatory Duchenne muscular dystrophy (DMD). METHODS: The consistency of changes in the 6-minute walk distance (Δ6MWD) was assessed across multiple clinical trial placebo arms and sources of NHD/RWD. Six placebo arms reporting 48-week Δ6MWD were identified via literature review and represented 4 sets of inclusion/exclusion criteria (n = 383 patients in total). Five sources of RWD/NHD were contributed by Universitaire Ziekenhuizen Leuven, DMD Italian Group, The Cooperative International Neuromuscular Research Group, ImagingDMD, and the PRO-DMD-01 study (n = 430 patients, in total). Mean Δ6MWD was compared between each placebo arm and RWD/NHD source after subjecting the latter to the inclusion/exclusion criteria of the trial for baseline age, ambulatory function, and steroid use. Baseline covariate adjustment was investigated in a subset of patients with available data. RESULTS: Analyses included ∼1,200 patient-years of follow-up. Differences in mean Δ6MWD between trial placebo arms and RWD/NHD cohorts ranged from -19.4 m (i.e., better outcomes in RWD/NHD) to 19.5 m (i.e., worse outcomes in RWD/NHD) and were not statistically significant before or after covariate adjustment. CONCLUSIONS: We found that Δ6MWD was consistent between placebo arms and RWD/NHD subjected to equivalent inclusion/exclusion criteria. No evidence for systematic bias was detected. These findings are encouraging for the use of RWD/NHD to augment, or possibly replace, placebo controls in DMD trials. Multi-institution collaboration through the Collaborative Trajectory Analysis Project rendered this study feasible.
引用
- Goemans N, Signorovitch J, Sajeev G, et al. Suitability of external controls for drug evaluation in Duchenne muscular dystrophy. Neurology. 2020. PMID: 32611643. doi:10.1212/WNL.0000000000010170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。